|
||
Address correspondence to Genhong Cheng, University of California, Los Angeles, Dept. of Microbiology, Immunology and Molecular Genetics, 8-240 Factor Building, 10833 Le Conte Avenue, Los Angeles, CA 90095. Phone: (310) 825-8896; Fax: (310) 206-5553; email: genhongc{at}microbio.ucla.edu
| Abstract |
|---|
|
|
|---|
Key Words: macrophage phagocytosis toll-like receptor scavenger receptor p38
In addition to direct pathogen uptake, other classes of PRRs, such and toll-like receptors (TLRs), play essential roles in activating signal transduction pathways leading to the killing and clearance of pathogens. TLRs recognize highly conserved, pathogen-coded molecular structures termed pathogen-associated molecular patterns (PAMPs; reference 3). A great deal has been learned in the past 10 years regarding specific recognition of microbial PAMPs by individual TLRs (4). For example, TLR4 recognizes LPS from gram-negative bacteria whereas TLR9 recognizes bacterial hypomethylated CpG DNA motifs. After ligand binding, all TLRs sequentially recruit the adaptor molecules myeloid differentiation factor 88 (MyD88), IL-1 receptorassociated kinase (IRAK), and tumor necrosis factor receptorassociated factor 6 (TRAF6). These adaptors in turn mediate the activation of the jun NH2-terminal kinase (JNK), nuclear factor (NF)-
Significant progress has been also made in describing the inflammatory and antimicrobial responses induced by individual TLRs (68). Inflammation is promoted by TLRs through the production of cytokines such as TNF-
In our current study, we demonstrate that numerous TLR ligands specifically enhance phagocytosis of bacteria such as Escherichia coli and Staphylococcus aureus, while exhibiting minimal effects on nonbacterial targets such as latex beads. Various TLRs differentially promote phagocytosis through induction of a phagocytic gene program, with TLR9 being the strongest mediator of this process and TLR3 being the weakest. In addition, we show that TLR-mediated induction of scavenger receptors (SRs) occurs through MyD88, IRAK4, and p38, and that activation of this pathway is essential for TLR promotion of phagocytosis. This mechanism appears to be evolutionarily conserved between mice and humans, suggesting that this pathway is a critical mediator of bacterial clearance by mammals after infection.
RNA Quantitation.
EMSA, Western Blotting, and GST Pulldown Assays.
Phagocytosis Assays.
Flow Cytometry, Laser Scanning Cytometry, and Fluorescence Microscopy.
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Bacterial infection is a major cause of illness and morbidity in multicellular organisms. In the innate immune system, macrophages play a key role in combating infection. Macrophages rely heavily on phagocytosis and subsequent degradation of microbes in order to help clear the body of invading pathogens (1). Pathogens are detected by macrophages through a variety of pattern recognition receptors (PRRs; reference 2). This, in turn, leads to receptor-mediated endocytosis, digestion of the pathogen, and presentation of antigens in the context of MHC.
B, p38, extracellular signalrelated kinase 1/2 (ERK 1/2), and phosphoinositide 3kinase signaling pathways leading to activation of inflammatory target genes (5).
and IL-Iß (9). TLR activation also promotes recruitment of inflammatory cells (10), and has been shown to mediate direct antimicrobial activity against intracellular bacteria (11). Moreover, a few studies have suggested that certain TLR ligands may play a role in modulating the ability of macrophages to bind extracellular bacteria (1214). However, the ability of various TLRs to directly modulate macrophage phagocytosis remains unclear, and no molecular mechanism for such a process has been described.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Cell Culture and Reagents.
Murine bone marrowderived macrophages (BMMs) were differentiated from marrow as described previously (6). A129 (IFNAR-1-/-; reference 15) and B6129SF2/J wild-type control mice were obtained from B&K Universal Ltd. and Jackson ImmunoReasearch Laboratories, respectively. Mice deficient in MyD88 and littermate controls were obtained from Shizuo Akira (University of Osaka, Osaka, Japan). C57/B6 mice were used for all experiments not involving the A129 or MyD88-deficient mice (Jackson ImmunoReasearch Laboratories). RAW 264.7 murine macrophage cells were cultured in DMEM media supplemented with 10% fetal bovine serum and 100 U/ml penicillin and 100 µg/ml streptomycin. THP-1 human monocytes were cultured in RPMI media supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Peripheral blood mononuclear cells were isolated from human whole blood using Ficoll-Paque (Amersham Biosciences) density gradient centrifugation following the manufacturer's recommended protocol. Monocytes were enriched using Percoll (Amersham Biosciences) density gradient centrifugation and then adhered onto plastic plates for 2 h in RPMI containing 1% fetal bovine serum (Hyclone). The nonadherent cells are washed off with PBS and the adherent cells are cultured in complete RPMI supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin, and treated with stimuli. Specific TLR activation was achieved using F-583 (Rd mutant) E. coli lipid A for TLR4 (Sigma-Aldrich), CpG oligonucleotides for TLR9 (Invitrogen), purified peptidoglycan (PGN) from Staphylococcus aureus (Sigma-Aldrich) for TLR2, polyinosinic acid (poly I):C for TLR3 (Amersham Biosciences), and imiquimod for TLR7 (Sequoia Research). ERK 1/2 and p38 were both inhibited using 10 µM uo126 or sb202190, respectively (Calbiochem). Poly I was obtained from Sigma-Aldrich and added to cells 1 h before bacterial challenge. Macrophage colony-stimulating factor (M-CSF)containing media was obtained by growing L929 cells 4 d past confluency and then harvesting the conditioned media.
For microarray studies, BMMs were treated with media or 1 ng/ml lipid A for 4 h or 1 µg/ml poly I:C or 100 nM CpG for 4 or 12 h. After stimulation, total RNA was extracted and labeled cRNA synthesized as described previously (6). The labeled cRNA was used to hybridize to Affymetrix Mu11K chip sets and data analyzed using Affymetrix Microarray Suite 4.0 data mining software. To identify PAMP-induced genes, comparisons were performed using the media-onlytreated sample as a baseline. Genes were considered induced if they displayed (a) a threefold change relative to baseline, (b) they had a poststimulation average difference (a value representing absolute expression level) of at least 500, and (c) they had an average difference change relative to baseline of at least 600 (roughly twice chip background). Average difference change values for genes involved in phagocytosis were processed using Cluster and data presented as a dendrogram using the Treeview program (www.rana.lbl.gov/EisenSoftware.htm). For quantitative realtime PCR (Q-PCR), total RNA was isolated and cDNA synthesized as described previously (6). PCR was then performed using the iCycler thermocycler (Bio-Rad). I
B
, L32, and intercellular adhesion molecule-1(ICAM-1) primers were the same as those described previously (6, 16). The following primers were synthesized by Invitrogen: macrophage SR with collagenous structure (MARCO) forward ATCCTGCTCACGGCAGGTACT, and reverse GCACATCTCTAGCATCTGGAGCT, scavenger receptor-A (SR-A1) forward TCCTTGCAGAGTCTGAATATGACACT, and reverse CCTCCTGTTGCTTTGCTGTAGATT, lectin-like oxidized LDL receptor (LOX-1) forward GTGGACACAATTACGCCAGGTA, and reverse GCCCTTCCAGGATACGATCC, and IL-1ß forward GAGCTGAAAGCTCTCCACCTCA, and reverse TCGTTGCTTGGCTCCTTGTAC. It is of note that we refer to SR-A1 mRNA as SR-A throughout this manuscript.
For EMSA, BMMs were stimulated with TLR ligands and nuclear extracts were prepared as described previously (17). For p38 and phosphorylated p38 immunoblotting, cells were lysed in modified RIPA buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate containing 2 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 100 µg/ml PMSF) containing protease and phosphatase inhibitors and 40 µg of protein was loaded per lane and separated by SDS-PAGE on 10% gels. After transfer, nitrocellulose filters were immunoblotted using anti-p38 and antiactivated p38 antibodies from Cell Signaling Technologies as per manufacturer's recommendations. A human pEFBOS.TLR9 construct was provided by Shizuo Akira. ESTs containing the intracellular domain of hTLR3 and full-length hMyD88 were obtained from Research Genetics. The cloning of the intracellular domains of TLR3 and TLR9 into expression vectors and binding assays were performed as described previously (16).
For each experiment, the green fluorescence protein (GFP)expressing E. coli (a gift from Dr. Jeff F. Miller, UCLA, Los Angeles, CA) were grown up from a single colony in Luria-Bertani broth containing 100 µg/ml ampicillin. The culture was then subcultured and grown until log phase growth was obtained. Bacteria were then washed in PBS two times and then resuspended at the appropriate concentration in either DMEM or RPMI media without serum or antibiotics. Before infection, macrophages were washed two times in media without serum or antibiotics before bacterial challenge. BMMs and RAW264.7 cells were infected with GFPE. coli at an multiplicity of infection (MOI) of 5 or 25, respectively. The optimal time point for measurement of phagocytosis was determined to be at 45 min after infection. Macrophage cells were then washed with cold PBS in order to stop additional bacterial uptake or destruction of bacteria in the phagolysosome. Cells were washed a total of three times in cold PBS before harvesting in cold PBS containing 5 mM EDTA. Cells were then fixed using paraformaldehyde (1% final concentration) and then subjected to FACS® analysis. Experiments using acetylated low-density lipoproteins (Molecular Probes), fluorescently labeled latex beads (Sigma-Aldrich), or BODIPY®conjugated S. aureus (Wood strain without protein A) BioParticles® (Molecular Probes) were performed in a similar fashion at 5 µg/ml, at an MOI of 1 or 10, respectively.
MARCO and SR-A protein expression on the macrophage cell surface was detected by using an anti-MARCOFITC antibody (clone ED31; 1 µg/ml, along with IgG1 isotype control), or antiSR-AFITC antibody (clone 2F8, which recognizes both SR-AI and SR-AII isoforms; 1 µg/ml, along with IgG2b isotype control), respectively. These antibodies, along with unconjugated antiSR-Ablocking antibody (clone 2F8), were obtained from Serotec, Inc. An anti-CD11c antibody conjugated to PE was obtained from Becton Dickinson. All staining antibodies were diluted in FACS® buffer (phosphate-buffered saline, 1% bovine serum albumin, 1% fetal calf serum, 0.1% sodium azide) containing 1% normal mouse serum. FACS® analysis was conducted using a FACSCaliber® (Becton Dickinson) machine and CellQuest software (Becton Dickinson). To assess changes in phagocytic efficiency, RAW 264.7 cells were plated in eight-well chamber slides (Nalge NUNC) and treated as indicated. Cells were fixed with 4% paraformaldehyde for 30 min and analyzed with a laser scanning cytometer (CompuCyte). Cells were counterstained with 6'-diamidino-2-phenylindole (DAPI; Molecular Probes) at a concentration of 10 µg/ml to identify DNA and to distinguish cell cycle stage. The UV laser was used to contour on DAPI using a minimum cell area of 20 µm. The argon laser was used to measure fluorescence of GFPE. coli shown as percent of cells that have been phagocytosed by macrophages. The number of GFPE. coli per cell was measured by laser scanning microscopy using ultraviolet light to excite DAPI and the argon laser was used to measure GFP fluorescence within a minimum of 2 pixels in area. LSC-based fluorescence in situ hybridization (FISH) analysis software was used to show the total number of GFPE. coli per macrophage. The LSC was used to photograph the GFPE. coli with a CCD camera and colored with CompuCyte color software (Laser Scanning Cytometry). For fluorescence microscopy a Leica DM IRBE fluorescent microscope using 10x and 63x objectives (Leica Microsystems) and Openlab software (Improvision) was used for image acquisition. Cells were counter stained with DAPI and then stained with rhodaminephalloidin (Molecular Probes) as per the manufacturer's protocol to label cytoskeletal F-actin.
![]()
Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TLR Ligands Specifically Enhance Phagocytosis of Bacteria.
To determine the role of TLRs in promoting phagocytosis, we pretreated RAW 264.7 murine macrophage cells with TLR ligands and measured the uptake of the GFP-labeled Topp10 strain of E. coli. We chose to perform these experiments using the RAW264.7 cell line because we found that these cells have a low basal level of phagocytosis as determined by FACS® (Fig. 1
A). As shown in Fig. 1 A, pretreatment of these cells with various TLR ligands markedly enhanced the level of phagocytosis of the gram-negative bacterium E. coli. We also found that TLR activation leads to increased uptake of BioParticles® derived from the gram-positive bacterium S. aureus (Fig. 1 C). Different TLRs promoted phagocytosis to different extents, with TLR9 being the strongest, followed by TLR2 and TLR7 (data not shown) and TLR4 and TLR3 being the weakest inducers of this process.
|
To determine if TLR-induced phagocytosis is an evolutionarily conserved process, we first tested the human monocyte cell line THP-1. Because human monocytes are unresponsive to CpG, we used the TLR2 ligand PGN as it was also a relatively strong inducer of phagocytosis in our murine studies and was also able to induce IL-12 p40 production (data not shown). Fig. 1 D demonstrates that PGN pretreatment significantly increased the ability of THP-1 cells to ingest E. coli. We next wanted to test if primary human monocytes also have increased phagocytic capabilities after TLR activation. PGN treatment was also able to significantly up-regulate phagocytosis in primary human monocytes, causing a roughly twofold increase in the percent of cells containing bacteria (Fig. 1 E). In addition, we noticed a correlation between the degree of IL-12 p40 induction (a control for efficient TLR2 stimulation and basal activation state of the monocytes used) and the level of increase in phagocytosis after PGN treatment (data not shown).
TLRs Induce Genes Involved in Phagocytosis.
To define the molecular mechanisms underlying the TLR-induced phagocytic phenotype observed in Fig. 1, we analyzed TLR-regulated target genes on a global basis. Murine bone marrowderived macrophage cells (BMMs) were treated with CpG, lipid A, and poly I:C for 4 and 12 h, and then subjected to a microarray analysis to assess target gene expression changes (Fig. 2
A). We selected the concentrations of TLR ligands used as they gave relatively equal activation of NF-
B by electrophoretic mobility shift assay (EMSA; Fig. 2 B, top), as well as equal up-regulation of I
B
mRNA, suggesting a similar strength of signal (Fig. 1 B, top). Upon analyzing the microarray results, we identified a number of genes that were up-regulated by TLR9, TLR4, and TLR3 that are involved in phagocytosis (Fig. 2 A). Genes such as CD36, thrombospondin, and the apoptotic cell clearance receptor are known to be involved in the clearance of apoptotic cells (1820). In addition, genes involved in opsonin-dependent phagocytosis (Fc and complement receptor genes as well as Lyn and Syk) were found to be up-regulated by TLRs (21, 22). We also noticed a number of genes involved in opsonin-independent phagocytosis of bacteria. Among these genes were a subset of SRs, including MARCO and SR-A (23). Genes coding for certain signaling molecules (Protein Kinase C
and Lyn) that are thought to act downstream of SRs were also up-regulated (24).
|
|
Recently, the serinethreonine kinase IRAK4 has been shown to be an important component of the MyD88-dependent pathway (27). To determine if the TLRMyD88 signal that is responsible for SR up-regulation is mediated through IRAK4, we stimulated BMMs deficient in IRAK4 with CpG and assessed the up-regulation of MARCO and LOX-1. Identical to MyD88 knockout BMMs, the IRAK4 deficiency ablated up-regulation of these TLR target genes (Fig. 3 A). This IRAK4 requirement was also verified at the protein level for MARCO (Fig. 3 B).
In an effort to determine which signaling pathway downstream from IRAK4 is required for SR gene expression, we used different pharmacological inhibitors to block known TLR signaling pathways including p38 (sb202190) and ERK 1/2 (uo126). We used a concentration of 10 µM for each of these inhibitors because we found that this concentration led only to inhibition of the intended pathway and did not nonspecifically affect other signaling pathways (unpublished results). Supporting this claim, ICAM-1 induction (whose transcription is NF-
B dependent) is not effected by treatment with sb202190 (Fig. 3 A). However, inhibition of p38 activity, but not ERK 1/2 activity, blocked TLR-induced expression of SR transcripts in response to CpG (Fig. 3 A). FACS® analysis shows that TLRs also potently up-regulate MARCO and SR-A at the protein level and that inhibition of p38 activity completely blocks this induction (Fig. 3, B and C). The effectiveness of uo126 is exemplified by the fact that TLR-induced IL-1ß transcription is greatly reduced after blockade of ERK 1/2 with this compound (Fig. 3 A).
In IRAK4-deficient mice, p38 activation is completely abolished after IL-1ß treatment (27). Additionally, it has been shown that CpG-mediated p38 activation is completely abolished in the absence of MyD88 (28). To determine if IRAK4 is also required for p38 activation downstream from TLR9, we treated IRAK4-/- BMMs with CpG and assessed p38 activation by conducting Western blotting using an antibody that specifically recognizes phosphorylated p38. We found that in the absence of IRAK4, p38 was no longer activated by TLR9 signaling (Fig. 3 D).
As previously mentioned, we had noticed that TLR9 was overall the strongest inducer of SR expression, whereas TLR3 was the weakest (Fig. 2, A and C). Because the signaling events leading to SR expression appear to be dependent on MyD88, we tested the relative affinities of the cytoplasmic domains of TLR3 and TLR9 for MyD88. We show in Fig. 3 E that the GSTTLR9 intracellular domain has a higher affinity for MyD88 than does GSTTLR3 intracellular domain using pulldown assays with overexpressed MyD88. Collectively, these data suggest that TLRs differentially up-regulate a subset of bacterial binding SRs via a MyD88IRAK4p38-dependent pathway. In addition, the strength of signaling activated by various TLRs may be determined by the relative affinity of these different TLRs for MyD88.
TLR-induced Bacterial Phagocytosis Is MyD88, p38, and SR Dependent.
To determine if TLR-induced phagocytosis of bacteria is dependent on MyD88IRAK4p38-mediated SR up-regulation, we first compared TLR-induced phagocytosis of bacteria by BMMs derived from wild-type and MyD88 knockout mice (Fig. 4
A). Although BMMs have a high basal level of phagocytosis relative to RAW 264.7 cells, which is likely due to up-regulation of SR-A by M-CSF in the culture media (data not shown; and references 29 and 30), CpG pretreatment still significantly increases bacterial uptake by BMMs in a MyD88-dependent manner. Interestingly, the basal level of BMM phagocytosis was significantly decreased in MyD88-/- macrophage cells compared with wild-type controls.
|
SR-A has been shown to play an important role in bacterial phagocytosis (29, 31). Furthermore, mice with a targeted disruption of the SR-A gene have defects in bacterial clearance (31). Thus, we sought to determine if TLR-inducible phagocytosis specifically involved SR-A. Fig. 4 C reveals that a blocking antibody against SR-A, but not the antibody isotype control, significantly reduced TLR-induced phagocytosis. Because the block was not complete, it implied that other SRs may be involved in the uptake of bacteria. To test if this is the case, we performed phagocytosis assays in the presence of the SR inhibitor, poly I. These experiments showed that TLR-inducible phagocytosis was almost completely inhibited by poly I and indicated that multiple SRs are, in fact, involved in the TLR-mediated potentiation of bacterial phagocytosis (Fig. 4 C). The involvement of multiple SRs in TLR9- and TLR2-induced bacterial phagocytosis correlates with a p38-dependent increase in expression of not only SR-A but also MARCO and LOX-1 after CpG treatment (Fig. 3, AC). These data imply that TLR-inducible macrophage phagocytosis of bacteria is through a MyD88IRAK4p38-dependent up-regulation of multiple SRs that, together, contribute to an overall increase in bacterial binding and phagocytosis.
TLR Activation Causes an Increase in Phagocytic Efficiency.
The broad shift in mean fluorescence intensity present in the FACS® data (Fig. 1 A) from our phagocytosis assays suggested that TLR ligand treatment may not only cause an increased number of macrophages able to participate in bacterial phagocytosis, but they also promote an increase in the amount of bacteria uptake by individual macrophage cells. Fluorescence microscopy confirmed this, showing that TLR ligand treatment of RAW 264.7 cells not only causes an increase in the number of cells engaged in phagocytosis, but also an enhancement in the number of E. coli taken up per individual macrophage cell (Fig. 5
A). We used LSC to quantitate the observed increase in the number of bacteria localized within individual macrophages (32). We found LSC to be comparable to FACS® in determining the percentage of TLR-induced phagocytic cells (data not shown). We performed an LSC-based FISH analysis, which enabled us to determine the topographic distribution of E. coli, and therefore allowed us to measure the number of bacteria bound or phagocytosed by each macrophage cell. These experiments showed quantitatively that CpG pretreatment of macrophages causes a great increase in the number of E. coli phagocytosed per individual macrophage, as compared with the media control (Fig. 5 B). In addition, treatment with sb202190 (sb) showed that this increase in phagocytic efficiency was found to be dependent on p38. Similar results were also obtained for cells pretreated with PGN. LSC-based FISH analysis revealed that human monocytes also take up a larger number of bacteria after TLR2 activation (data not shown). Our data suggest that all TLR ligands tested can induce macrophage phagocytosis of E. coli to varying degrees. Interestingly, TLR2 and TLR9 caused the greatest increase in bacterial uptake, with TLR9 being the strongest potentiator out of all of the TLRs tested. Furthermore, we found that TLR-induced nonopsonized phagocytosis can increase both the number of phagocytic cells in the population as well as the number of E. coli taken up on a per cell basis.
|
| Discussion |
|---|
|
|
|---|
We have identified a TLR-inducible gene subset that is indicative of enhanced macrophage bacterial binding and uptake. Among this subset of genes are SRs including SR-A, LOX-1, and MARCO. The role of SR-A in TLR-induced phagocytosis was demonstrated by using a blocking antibody specific for SR-A. Indeed, mice with targeted disruption of the SR-A gene have defects in bacterial clearance (31). The fact that the general SR inhibitor poly I can further inhibit TLR-induced phagocytosis in both human and mouse cells suggests that other SRs must assist SR-A in binding and phagocytosing of bacteria. In addition to SRs, TLRs mediate the induction of other genes involved in the recognition of pathogens and apoptotic cells including the mannose-6-phosphate receptor, ABC1, complement receptors (3338). The microarray results also demonstrate that each TLR tested can induce both common and specific genes involved in phagocytosis, which suggests that different TLRs can induce unique combinations of phagocytic mediators that may differentially target pathogens.
Our data support a model whereby TLRs transduce signals through MyD88, IRAK4, and p38 resulting in the up-regulation of SRs, leading to a significant increase in macrophage/monocyte phagocytosis of gram-negative and -positive bacteria. The TLR-mediated increase in phagocytosis appears to be specific for bacteria since only a slight increase in uptake of either latex beads or acetylated low-density lipoproteins was observed. These data are especially interesting since uptake of acetylated low-density lipoproteins is also mediated by SRs and suggest that TLRs may be able to differentially regulate the ability of SRs to mediate uptake of different ligands.
Our gene expression data reveal that although TLR3, TLR4, and TLR9 all induce expression of SRs, TLR9 appears to be the strongest inducer of SR-A, MARCO, and LOX-1, as well as of phagocytosis. Because the induction of these genes and phagocytosis of E. coli is dependent on MyD88, it is not surprising that TLR9 has a high relative affinity for this adaptor (Fig. 3 E). MARCO, LOX-1, and SR-A were analyzed specifically in this manuscript because they were all TLR induced, had steady-state mRNA, and protein levels that were dependent on the same signaling cascade (MyD88IRAK4p38), and have all been shown to be able to bind bacteria, including E. coli and S. aureus (23). Despite these similarities, each of these SR genes displayed differential induction kinetics, thus further studies will be required to understand the additional mechanisms controlling their TLR-induced expression. Regardless, it is evident that SRs are critical players in TLR-induced macrophage phagocytosis of bacteria, and that they work in a concerted manner. Besides TLR ligands, other stimuli may also induce the surface expression of SRs. Previous and current studies revealed that the SR levels are also up-regulated in response to M-CSF, which explains why bone marrowderived murine macrophages (cultured in M-CSF) have relatively high levels of SR expression compared with RAW 264.7 cells (cultured without M-CSF [data not shown]; references 28 and 29). There is even a possible relationship between TLRs and M-CSF, as our gene chip data indicated that all TLRs tested can induce expression of M-CSF (data not shown). It is important to emphasize that, besides the up-regulation of SRs, TLRs may likely up-regulate the expression or activity of other molecules involved in phagocytosis, which may not be able to be induced by other stimuli such as M-CSF.
A number of reports have shown that both murine and human TLRs play a vital role in host antibacterial responses. Systemic administration of CpG to bacterially infected wild-type mice results in the suppression of bacterial load (data not shown; and reference 39). Additionally, mice deficient in either MyD88 or IRAK4 have shown increased susceptibility to bacterial infection (27, 40). Recent studies have also revealed that a mutation in the human IRAK4 gene is linked to the inability to clear bacterial infections (41), and specific polymorphisms in human TLR2 result in hyporesponsiveness to bacterial ligands and impaired bacterial clearance by the host (4244). It is well known that TLRs and the MyD88 signaling pathway play critical roles in pro-inflammatory cytokine production, which is essential for antimicrobial responses. The data presented in this manuscript provide an additional explanationthat TLRs play an important role in promoting clearance of bacteria through the up-regulation of macrophage phagocytic activity through MyD88, IRAK4, and p38.
| Acknowledgments |
|---|
R. O'Connell was supported by the United States Public Health Service National Research Service Award GM07185. S.A. Vaidya was supported by a UCLA Medical Scientist Training Program training grant (GM 08042). E.K. Chow was supported by the UCLA ACCESS Graduate Program. G. Cheng is a Research Scholar supported by the Leukemia and Lymphoma Society of America. W.-C. Yeh was supported by an operating grant from Canadian Institutes of Health Research (MOP-57734). T. Lane was supported by the National Institutes of Health research grant S10 RR15862-01 and Stop Cancer II, and G. Miranda was supported by the Department of Defense grant OC 98-0006. Part of this work was also supported by National Institutes of Health research grants R01 CA87924 and R37 AI47868.
Submitted: July 23, 2003
Accepted: November 4, 2003
| Footnotes |
|---|
Abbreviations used in this paper: BMM, bone marrowderived macrophage; DAPI, 6'-diamidino-2-phenylindole; ERK 1/2, extracellular signalrelated kinase 1/2; FISH, fluorescence in situ hybridization; GFP, green fluorescence protein; ICAM-1, intercellular adhesion molecule-1; IRAK, IL-1 receptorassociated kinase; LOX-1, lectin-like oxidized LDL receptor; MARCO, macrophage scavenger receptor with collagenous structure; M-CSF, macrophage colony-stimulating factor; MOI, multiplicity of infection; MyD88, myeloid differentiation factor 88; NF, nuclear factor; PGN, peptidoglycan; poly I, polyinosinic acid; PRR, pattern recognition receptor; Q-PCR, quantitative realtime PCR; SR, scavenger receptor; SR-A, scavenger receptor-A; TLR, toll-like receptor; TRAF6, tumor necrosis factor receptorassociated factor 6.
| References |
|---|
|
|
|---|
1 Sansonetti, P. 2001. Phagocytosis of bacterial pathogens: implications in the host response. Semin. Immunol. 13:381390.[CrossRef][Medline]
2 Gordon, S. 2002. Pattern recognition receptors: doubling up for the innate immune response. Cell. 111:927930.[CrossRef][Medline]
3 Janeway, C.A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197216.[CrossRef][Medline]
4 Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675680.[CrossRef][Medline]
5 Takeuchi, O., and S. Akira. 2001. Toll-like receptors: their physiological role and signal transduction system. Int. Immunopharmacol. 1:625635.[CrossRef][Medline]
6 Doyle, S., S. Vaidya, R. O'Connell, H. Dadgostar, P. Dempsey, T. Wu, G. Rao, R. Sun, M. Haberland, R. Modlin, and G. Cheng. 2002. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 17:251263.[CrossRef][Medline]
7 Gao, J.J., V. Diesl, T. Wittmann, D.C. Morrison, J.L. Ryan, S.N. Vogel, and M.T. Follettie. 2002. Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J. Leukoc. Biol. 72:12341245.
8 Suzuki, T., S. Hashimoto, N. Toyoda, S. Nagai, N. Yamazaki, H.-Y. Dong, J. Sakai, T. Yamashita, T. Nukiwa, and K. Matsushima. 2000. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood. 96:25842591.
9 Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 11:115122.[CrossRef][Medline]
10 Netea, M.G., C.A. Van Der Graaf, A.G. Vonk, I. Verschueren, J.W. Van Der Meer, and B.J. Kullberg. 2002. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. 185:14831489.[CrossRef][Medline]
11 Thoma-Uszynski, S., S. Stenger, O. Takeuchi, M.T. Ochoa, M. Engele, P.A. Sieling, P.F. Barnes, M. Rollinghoff, P.L. Bolcskei, M. Wagner, et al. 2001. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science. 291:15441547.
12 Utaisincharoen, P., W. Kespichayawattana, N. Anuntagool, P. Chaisuriya, S. Pichyangkul, A.M. Krieg, and S. Sirisinha. 2003. CpG ODN enhances uptake of bacteria by mouse macrophages. Clin. Exp. Immunol. 132:7075.[CrossRef][Medline]
13 Dalpke, A.H., M.K. Schafer, M. Frey, S. Zimmermann, J. Tebbe, E. Weihe, and K. Heeg. 2002. Immunostimulatory CpG-DNA activates murine microglia. J. Immunol. 168:48544863.
14 Souza, M.C., M. Correa, S.R. Almeida, J.D. Lopes, and Z.P. Camargo. 2001. Immunostimulatory DNA from Paracoccidioides brasiliensis acts as T-helper 1 promoter in susceptible mice. Scand. J. Immunol. 54:348356.[CrossRef][Medline]
15 Muller, U., U. Steinhoff, L.F. Reis, S. Hemmi, J. Pavlovic, R.M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science. 264:19181921.
16 Doyle, S.E., R. O'Connell, S.A. Vaidya, E.K. Chow, K. Yee, and G. Cheng. 2003. Toll-like receptor 3 mediates a more potent antiviral response than toll-like receptor 4. J. Immunol. 170:35653571.
17 Lee, H., H. Dadgostar, Q. Cheng, J. Shu, and G. Cheng. 1999. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl. Acad. Sci. USA. 96:91369141.
18 Brown, E.J., and W.A. Frazier. 2001. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11:130135.[CrossRef][Medline]
19 Krieser, R.J., and K. White. 2002. Engulfment mechanism of apoptotic cells. Curr. Opin. Cell Biol. 14:734738.[CrossRef][Medline]
20 Febbraio, M., D.P. Hajjar, and R.L. Silverstein. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108:785791.[CrossRef][Medline]
21 Underhill, D.M., and A. Ozinsky. 2002. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20:825852.[CrossRef][Medline]
22 García-García, E., and C. Rosales. 2002. Signal transduction during Fc receptor-mediated phagocytosis. J. Leukoc. Biol. 72:10921108.
23 Peiser, L., S. Mukhopadhyay, and S. Gordon. 2002. Scavenger receptors in innate immunity. Curr. Opin. Immunol. 14:123128.[CrossRef][Medline]
24 Peiser, L., and S. Gordon. 2001. The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. Microbes Infect. 3:149159.[CrossRef][Medline]
25 Dempsey, P.W., S.A. Vaidya, and G. Cheng. 2003. The art of war: innate and adaptive immune responses. Cell. Mol. Life Sci. 60:118.[CrossRef][Medline]
26 Takeda, K., and S. Akira. 2003. Toll receptors and pathogen resistance. Cell. Microbiol. 5:143153.[CrossRef][Medline]
27 Suzuki, N., S. Suzuki, G.S. Duncan, D.G. Millar, T. Wada, C. Mirtsos, H. Takada, A. Wakeham, A. Itie, S. Li, et al. 2002. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature. 416:750756.[CrossRef][Medline]
28 Alexopoulou, L., A.C. Holt, R. Medzhitov, and R.A. Flavell. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 413:732738.[CrossRef][Medline]
29 Peiser, L., P.J. Gough, T. Kodama, and S. Gordon. 2000. Macrophage class A scavenger receptor-mediated phagocytosis of Escherichia coli: role of cell heterogeneity, microbial strain, and culture conditions in vitro. Infect. Immun. 68:19531963.
30 de Villiers, W.J., I.P. Fraser, D.A. Hughes, A.G. Doyle, and S. Gordon. 1994. Macrophage-colony-stimulating factor selectively enhances macrophage scavenger receptor expression and function. J. Exp. Med. 180:705709.
31 Thomas, C.A., Y. Li, T. Kodama, H. Suzuki, S.C. Silverstein, and J. El Khoury. 2000. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J. Exp. Med. 191:147156.
32 Darzynkiewicz, Z., E. Bedner, X. Li, W. Gorczyca, and M.R. Melamed. 1999. Laser-scanning cytometry: a new instrumentation with many applications. Exp. Cell Res. 249:112.[CrossRef][Medline]
33 Hamon, Y., C. Broccardo, O. Chambenoit, M.F. Luciani, F. Toti, S. Chaslin, J.M. Freyssinet, P.F. Devaux, J. McNeish, D. Marguet, and G. Chimini. 2000. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine. Nat. Cell Biol. 2:399406.[CrossRef][Medline]
34 Le Cabec, V., S. Carreno, A. Moisand, C. Bordier, and I. Maridonneau-Parini. 2002. Complement receptor 3 (CD11b/ CD18) mediates type I and type II phagocytosis during nonopsonic and opsonic phagocytosis, respectively. J. Immunol. 169:20032009.
35 Takizawa, F., S. Tsuji, and S. Nagasawa. 1996. Enhancement of macrophage phagocytosis upon iC3b deposition on apoptotic cells. FEBS Lett. 397:269272.[CrossRef][Medline]
36 van der Laan, L.J., S.R. Ruuls, K.S. Weber, I.J. Lodder, E.A. Dopp, and C.D. Dijkstra. 1996. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J. Neuroimmunol. 70:145152.[CrossRef][Medline]
37 Saraiva, E.M., A.F. Andrade, and W. de Souza. 1987. Involvement of the macrophage mannose-6-phosphate receptor in the recognition of Leishmania mexicana amazonensis. Parasitol. Res. 73:411416.[CrossRef][Medline]
38 Syme, R.M., J.C. Spurrell, E.K. Amankwah, F.H. Green, and C.H. Mody. 2002. Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes. Infect. Immun. 70:59725981.
39 Weighardt, H., C. Feterowski, M. Veit, M. Rump, H. Wagner, and B. Holzmann. 2000. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J. Immunol. 165:45374543.
40 Takeuchi, O., K. Hoshino, and S. Akira. 2000. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 165:53925396.
41 Picard, C., A. Puel, M. Bonnet, C.L. Ku, J. Bustamante, K. Yang, C. Soudais, S. Dupuis, J. Feinberg, C. Fieschi, et al. 2003. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 299:20762079.
42 Bochud, P.Y., T.R. Hawn, and A. Aderem. 2003. Cutting edge: a toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J. Immunol. 170:34513454.
43 Lorenz, E., J.P. Mira, K.L. Cornish, N.C. Arbour, and D.A. Schwartz. 2000. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 68:63986401.
44 Kang, T.J., and G.T. Chae. 2001. Detection of toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol. Med. Microbiol. 31:5358.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|